Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

82.54

-0.76 (-0.91%)

At close: Jul 31, 2026, 4:00 PM EDT

82.57

+0.03 (0.04%)

After-hours: Jul 31, 2026, 7:34 PM EDT

Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	309.75	133.82	115.85	118.37	234.2	118.72
Short-Term Investments	8.87	9	480.22	217.63	128.6	622.2
Cash & Short-Term Investments	318.62	142.82	596.07	336	362.79	740.92
Cash Growth	-57.40%	-76.04%	77.40%	-7.38%	-51.03%	101.33%
Accounts Receivable	457.99	441.27	308.46	234.21	231.07	90.98
Inventory	155.47	176.48	141.86	127.6	100.12	53.91
Other Current Assets	70.96	64.64	38.95	48.61	45.02	40.48
Total Current Assets	1,003	825.21	1,085	746.42	739.01	926.29
Net Property, Plant & Equipment	82.23	82.14	75.04	74.94	75.57	8.79
Other Intangible Assets	951.96	981.47	401.83	472.88	546.65	-
Goodwill	582.32	580.36	416.82	416.82	409.05	-
Other Long-Term Assets	53.18	56.15	84.45	22.2	71.23	169.35
Total Assets	2,673	2,525	2,063	1,733	1,842	1,104

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	14.1	20.9	10.25	11.82	17.69	1.54
Accrued Expenses	140.37	156.19	128.85	100.68	99.76	24.44
Current Portion of Long-Term Debt	208.74	-	-	-	13.33	89.42
Unearned Revenue	-	-	-	-	-	1.75
Total Current Liabilities	363.21	177.09	139.1	112.49	130.79	117.15
Long-Term Debt	1,936	2,143	1,506	1,499	1,493	787.26
Other Long-Term Liabilities	153.98	156.79	54.76	37.72	48.16	3.07
Total Long-Term Liabilities	2,090	2,299	1,561	1,537	1,541	790.33
Total Liabilities	2,453	2,477	1,700	1,649	1,672	907.48

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.12	0.12	0.12	0.13	0.14	0.14
Additional Paid-in Capital	27.39	12	-	2.41	27.37	256.35
Accumulated Other Comprehensive Income	-12.7	-18.09	3.83	-9.28	-0.92	-0.62
Retained Earnings	204.84	54.79	359.87	90.55	143.22	-58.91
Shareholders' Equity	219.64	48.81	363.82	83.81	169.8	196.95
Total Liabilities & Equity	2,673	2,525	2,063	1,733	1,842	1,104

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	2,145	2,143	1,506	1,499	1,506	876.67
Net Cash (Debt)	-1,826	-2,000	-909.72	-1,163	-1,143	-135.75
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-15.00	-16.14	-7.03	-8.67	-8.13	-0.93
Book Value	219.64	48.81	363.82	83.81	169.8	196.95
Book Value Per Share	1.80	0.39	2.81	0.62	1.21	1.34
Tangible Book Value	-1,315	-1,513	-454.83	-805.89	-785.9	196.95
Tangible Book Value Per Share	-10.80	-12.21	-3.51	-6.01	-5.59	1.34

SEC Filings: 10-K · 10-Q